title: Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma.
abstract: OBJECTIVE
  Treatment by octreotide has been suggested in medullary thyroid carcinoma patients with post-surgery metastases. The purpose of this study was to evaluate if the tumoral regression could be improved by a high dose and by prolonged octreotide treatment.
  
  
  METHODS
  Fourteen thyroidectomized patients were studied. All patients had persistently elevated plasma calcitonin levels with normal or elevated carcino-embryonic antigen levels. Five hundred micrograms/day of octreotide were administered by continuous subcutaneous infusion for 90 days.
  
  
  METHODS
  Plasma calcitonin and carcino-embryonic antigen levels were determined at days -30, -20, -2, -1, 0, +30, +60, +90, +120; morphological extension was evaluated every month.
  
  
  RESULTS
  Continuous infusion of octreotide did not induce any significant decrease of calcitonin levels, or any morphological improvement, and had no major undesirable effect. However, in 4/14 patients calcitonin levels fell during treatment (-43, -50, -15, -20%), and in 9 patients calcitonin increased (+22 to +130%) after cessation of therapy.
  
  
  CONCLUSIONS
  Biological or morphological parameters of medullary thyroid carcinoma are not significantly improved in a large series of patients treated by octreotide.
authors.affiliation: Département d'endocrinologie, Hopital Avicenne, Bobigny, France.
authors.forename: E
authors.initials: E
authors.lastname: Modigliani
authors.forename: R
authors.initials: R
authors.lastname: Cohen
authors.forename: S
authors.initials: S
authors.lastname: Joannidis
authors.forename: C
authors.initials: C
authors.lastname: Siame-Mourot
authors.forename: J M
authors.initials: JM
authors.lastname: Guliana
authors.forename: G
authors.initials: G
authors.lastname: Charpentier
authors.forename: D
authors.initials: D
authors.lastname: Cassuto
authors.forename: M
authors.initials: M
authors.lastname: Bentata Pessayre
authors.forename: A
authors.initials: A
authors.lastname: Tabarin
authors.forename: P
authors.initials: P
authors.lastname: Roger
mesh_terms: D000328:Adult; D002116:Calcitonin / Q000097:blood; D002277:Carcinoma / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015918:Infusion Pumps, Implantable; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015282:Octreotide / Q000008:administration & dosage*; D013964:Thyroid Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D013965:Thyroidectomy; D013997:Time Factors
chemical_list: D002116:Calcitonin; D015282:Octreotide